Furthermore, males have been reported to have better responses to ICI treatment on its own (34) while females had a significantly larger benefit when anti-PD1 therapy is combined with chemotherapy for treatment of lung cancer (14, 35). This evidence concerns the gene PDCD1 and lung carcinoma.